Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. 10 stocks we like better than Eli ...

Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs doubled, and they are key components of the company's business. The stock ...

Eli Tomac was involved in a first-turn crash in Round 5 of the SuperMotocross World Championship at State Farm Stadium in Glendale, Arizona, and was slow to rise. After remounting his KTM in 22nd, he ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...

Eli Lilly delivered robust Q4 results, with revenue up 43% YoY and EPS beating consensus by $0.61. LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and ...

INDIANAPOLIS — Researchers in Indianapolis are launching a first-of-its-kind study when it comes to GLP-1 drugs and the impact on the workplace. In a week-long series, WRTV Investigates is digging ...

Eli Tomac of Cortez silenced doubts about his age and new team by dominating the opening race Saturday in the 2026 Supercross season after joining the Red Bull KTM Racing team. The win at Angel ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Eli Lilly is building its prospects in immunology through the $1.2 billion acquisition of Ventyx Biosciences, a clinical-stage company with drugs addressing a promising target offering the potential ...

The company has seen revenue soar in recent quarters thanks to its weight loss portfolio. Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 ...